ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
HRTX
|
Total knee arthroplasty
|
Phase 2b
|
2018-06-21 00:00:00
|
Phase 2 data released June 21, 2018. Primary endpoint met.
| 0 |
RGNX
|
Wet AMD using suprachoroidal delivery
|
Phase 2
|
2023-07-30 00:00:00
|
Phase 2 additional data reported meaningful reductions in Anti-VEGF injection burden with stable to improved CRT through month 6, noted July 30, 2023.
| 1 |
GOVX
|
COVID-19 in immunocompromised patients
|
Phase 2
|
2023-10-30 00:00:00
|
Phase 2 site expansion commenced, noted Otober 30, 2023.
| 0 |
VBIV
|
COVID-19 vaccine
|
Phase 1/2
|
2021-06-29 00:00:00
|
Phase 1/2 initial data released June 29, 2021 - well-tolerated with no safety signals observed and induced neutralization titers in 100% of participants.
| 1 |
TVTX
|
IgA nephropathy
|
Approved
|
2023-02-17 00:00:00
|
FDA accelerated approval on February 17, 2023.
| 1 |
KPTI
|
Myelodysplastic syndrome (MDS), hypomethylating agents (HMA) refractory
|
Phase 2
|
2023-05-03 00:00:00
|
Phase 2 data reported that treatment demonstrated a 27% overall response rate (ORR) in the intent-to-treat (ITT) population and a 31% ORR in the efficacy evaluable population, noted May 3, 2023.
| 1 |
ESPR
|
Cardiovascular Diseases
|
Phase 3
|
2023-08-26 00:00:00
|
Phase 3 total event data presented at ESC reported that bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3, noted August 26, 2023.
| 1 |
CGEM
|
Acute myeloid leukemia (AML)
|
Phase 1
|
2023-06-08 00:00:00
|
Preliminary safety data from an ongoing first-in-human study were published in abstract form as part of the 2023 EHA Congress in June 2023.
| 0 |
CORT
|
Pancreatic cancer
|
Phase 3
|
2021-06-22 00:00:00
|
Phase 3 initial data released June 22, 2021. 2/31 (6%) partial responses. Enrollment to be stopped. Level of benefit does not justify further study.
| -1 |
ABBV
|
Ulcerative Colitis
|
Phase 3
|
2023-06-15 00:00:00
|
Phase 3 trial met primary and secondary endpoints, noted June 15, 2023.
| 0 |
EYPT
|
Non-infectious uveitis
|
Approved
|
2018-10-15 00:00:00
|
FDA approval announced October 15, 2018.
| 1 |
GSK
|
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
|
CRL
|
2017-10-26 00:00:00
|
CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission.
| 1 |
INO
|
Cervical high-grade squamous intraepithelial lesions (HSIL)
|
Phase 3
|
2023-03-01 00:00:00
|
Phase 3 trial did not achieved in the investigational biomarker-selected population for the endpoint of lesion regression and viral clearance, noted March 1, 2023.
| 1 |
AGEN
|
Cervical cancer
|
BLA Filing
|
2021-10-22 00:00:00
|
BLA voluntarily withdrawn October 22, 2021.
| 0 |
TEVA
|
Tourette Syndrome
|
Phase 2/3
|
2020-02-19 00:00:00
|
Phase 2/3 trial did not meet primary endpoint - February 19, 2020.
| 1 |
ONCS
|
Melanoma - cancer
|
Phase 2b
|
2020-11-09 00:00:00
|
Phase 2b interim data presented at SITC November, 2020. 20% ORR.
| 1 |
SGMO
|
Sickle Cell Disease
|
Phase 1/2
|
2021-12-13 00:00:00
|
Phase 1/2 data reported that total hemoglobin stabilized by Week 26 after treatment in all four patients. Fetal hemoglobin level increased from 0.1-11% at screening to 14-39% in all four patients and was 38% in the longest-treated patient at 91 weeks, noted December 13, 2021.
| 1 |
ALDX
|
Allergic conjunctivitis
|
Phase 3
|
2023-06-15 00:00:00
|
Phase 3 top-line data met primary and all secondary endpoints, noted on June 15, 2023.
| 0 |
RHHBY
|
Acute uncomplicated influenza (12 years and older)
|
Approved
|
2020-11-23 00:00:00
|
FDA approval announced November 23, 2020.
| 1 |
UTHR
|
Pulmonary arterial hypertension (PAH)
|
Phase 3
|
2019-04-08 00:00:00
|
Phase 3 data released April 8, 2019 did not meet primary endpoint.
| 1 |
NBIX
|
Tourette syndrome - juvenile
|
Phase 2b
|
2018-12-12 00:00:00
|
Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.
| 1 |
VALN
|
COVID-19 vaccine
|
Phase 3
|
2023-03-02 00:00:00
|
Phase 3 data reported that the fold decline of neutralizing antibodies over six months after a second vaccination with VLA2001 was similar to the active comparator, and less pronounced than for other licensed COVID-19 vaccines, noted March 2, 2023.
| 0 |
LIFE
|
COVID-19
|
Phase 2
|
2021-01-04 00:00:00
|
Phase 2 data released January 4, 2021. Primary safety endpoint met. Median time to recovery of 5.5 days compared to 6 days in the placebo group.
| 0 |
IPSEY
|
Primary biliary cholangitis (PBC)
|
Phase 3
|
2023-06-30 00:00:00
|
Phase 3 data reported that trial met primary endpoint, noted June 30, 2023.
| 0 |
VALN
|
Chikungunya Vaccine
|
Phase 3
|
2021-12-21 00:00:00
|
Phase 3 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination.
| 1 |
ELTX
|
Acute Kidney Injury associated with cardiac surgery
|
Phase 2
|
2021-12-09 00:00:00
|
Phase 2 data demonstrated that trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).
| 1 |
RCKT
|
Pyruvate Kinase Deficiency (PKD)
|
Phase 1
|
2023-05-19 00:00:00
|
Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023.
| 1 |
VTVT
|
Type 1 Diabetes
|
Phase 2
|
2021-10-12 00:00:00
|
Phase 2 mechanistic study data demonstrated that treated patients experienced no increase in ketone levels relative to placebo during a period of acute insulin withdrawal, indicating no increased risk of ketoacidosis. Study met primary endpoint, noted October 12, 2021.
| 1 |
MRTX
|
Nonsquamous (NSQ) Non–Small-Cell Lung Cancer (NSCLC)
|
Phase 2
|
2021-09-20 00:00:00
|
Phase 2 data demonstrated that the median PFS was 5.7 months and the median overall survival (OS) was 14.9 months, with 56% and 32% of these patients alive at one year and two years, respectively. ORR was 18%, with 3% CR and 15% PR. The median DOR was 12.8 months, presented at ESMO September 20, 2021.
| 1 |
CYTK
|
Heart failure with reduced ejection fraction (HFrEF)
|
Phase 3
|
2022-04-03 00:00:00
|
Phase 3 results reported that there was no change in pVO2 in patients treated with omecamtiv mecarbil versus placebo, noted April 3, 2022.
| 1 |
OGEN
|
Oral mucositis (OM)
|
Phase 2
|
2020-04-15 00:00:00
|
Phase 2 data released April 15, 2020 did not meet primary endpoint.
| 1 |
CRVS
|
Renal cell cancer
|
Phase 1/2
|
2020-05-29 00:00:00
|
Phase 1b/2 initial data from the RCC cohort at ASCO May 29, 2020. AdenoSig positive group -ORR of 17%. AdenoSig negative group - no partial responses.
| 0 |
CYTK
|
Symptomatic obstructive hypertrophic cardiomyopathy (HCM)
|
Phase 3
|
2023-06-20 00:00:00
|
Phase 3 enrollment open, noted June 20, 2023.
| 0 |
TBPH
|
Neurogenic Orthostatic Hypotension (nOH)
|
Phase 3
|
2021-09-15 00:00:00
|
Phase 3 study did not meet its primary endpoint September 15, 2021.
| 1 |
REGN
|
Rheumatoid arthritis
|
Approved
|
2017-05-22 00:00:00
|
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
| 1 |
VIRX
|
Nasopharyngeal carcinoma and Epstein-Barr Virus-Positive (EBV+) Solid Tumors
|
Phase 1/2
|
2022-12-09 00:00:00
|
Preliminary Phase 1b/2 safety data reported no DLTS with 2/6 patients achieving stable disease, noted November 30, 2022.
| 1 |
FMTX
|
Acute myeloid leukemia
|
Approved
|
2022-12-01 00:00:00
|
Approved December 1, 2022.
| 1 |
NKTR
|
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
|
Phase 1/2
|
2019-11-09 00:00:00
|
Phase 1/2 updated data at SITC November 9, 2019 noted ORR was 53% (20/38) with 34% (13/38) complete response (CR) rate.
| 0 |
JNJ
|
Ulcerative colitis
|
Approved
|
2019-10-21 00:00:00
|
FDA Approval announced October 21, 2019.
| 1 |
PLRX
|
Primary sclerosing cholangitis (PSC)
|
Phase 2a
|
2023-09-26 00:00:00
|
Phase 2a met its primary and secondary endpoints at the 12-week treatment period, noted September 26. 2023.
| 1 |
VTRS
|
Dry eye disease
|
Approved
|
2021-10-18 00:00:00
|
Approved October 18, 2021.
| 1 |
AZN
|
Non-small cell lung cancer (NSCLC)
|
Phase 2
|
2021-09-17 00:00:00
|
Phase 2 trial met primary endpoint of confirmed ORR of 30%, and for durvalumab plus monalizumab 36%. The 10-month PFS rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone, September 17, 2021.
| 0 |
BHVN
|
Acute treatment of migraine
|
Approved
|
2020-02-27 00:00:00
|
FDA Approval announced February 27, 2020.
| 1 |
NKTR
|
Gram-Negative Pneumonia (INHALE 1)
|
Phase 3
|
2017-11-24 00:00:00
|
Phase 3 data released November 24, 2017. Endpoints not met.
| 0 |
GTHX
|
Second/third-line small-cell lung cancer
|
Approved
|
2021-02-12 00:00:00
|
FDA approval announced February 12, 2021.
| 1 |
OTLK
|
Wet age-related macular degeneration (wet AMD)
|
BLA Filing
|
2023-11-02 00:00:00
|
The FDA informed the company that an additional adequate and well-controlled clinical trial would be required for the approval of ONS-5010 for wet AMD. Resubmission of the ONS-5010 BLA as early year end 2024, noted November 2, 2023.
| 1 |
LLY
|
Chronic low back pain
|
Phase 3
|
2019-02-19 00:00:00
|
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
| 1 |
PCVX
|
Invasive Pneumococcal Disease (IPD)
|
Phase 1/2
|
2023-10-19 00:00:00
|
IND cleared by FDA, noted October 19, 2023
| 0 |
HALO
|
Multiple myeloma
|
Approved
|
2020-05-01 00:00:00
|
FDA Approval announced May 1, 2020.
| 1 |
LGND
|
Relapsed Multiple Myeloma
|
Approved
|
2018-06-11 00:00:00
|
sNDA approval announced June 11, 2018.
| 1 |
AZN
|
Neurofibromatosis type 1 plexiform neurofibromas
|
Approved
|
2020-04-13 00:00:00
|
FDA Approval announced April 13, 2020.
| 1 |
GLTO
|
Non-small cell lung cancer (NSCLC)
|
Phase 2a
|
2023-10-23 00:00:00
|
Phase 2a data reported that the objective tumor responses (defined as partial responses per RECIST criteria 1.1) were observed in three of five patients (60%) who received GB1211 for at least three weeks, noted October 23, 2023
| 1 |
ZVRA
|
induced Vasomotor Symptoms (iVMS) associated with menopause
|
Phase 1
|
2023-03-17 00:00:00
|
Phase 2a PoC did not meet its primary endpoint of ability to decrease the frequency or severity of hot flashes in postmenopausal women. As a result, the company is pausing the program until a full dataset review, noted March 17, 2023
| 1 |
NEXI
|
Multiple Myeloma
|
Phase 1/2
|
2021-12-12 00:00:00
|
Phase 1/2 data reported that treatment is well-tolerated without dose-limiting toxicities, noted December 12, 2021.
| 1 |
NVS
|
Paroxysmal nocturnal hemoglobinuria (PNH)
|
Phase 3
|
2022-12-13 00:00:00
|
Phase 3 data reported that trial met both primary endpoints, noted December 13, 2022.
| 0 |
LLY
|
Non-radiographic axial spondyloarthritis
|
Approved
|
2020-06-01 00:00:00
|
FDA Approval announced June 1, 2020.
| 1 |
IMNN
|
Ovarian cancer
|
Phase 1/2
|
2023-09-28 00:00:00
|
Phase 1/2 interim data reported efficacy trends in PFS, demonstrating a delay in disease progression in the treatment arm of approximately 33% compared with the control arm, with the hazard ratio nearing the required value. Preliminary OS data follows a similar trend, showing an approximate 9-month improvement in the treatment arm over the control arm, noted September 28, 2023.
| 1 |
OCUP
|
Mydriasis (RM)
|
Approved
|
2023-09-27 00:00:00
|
FDA Approval on September 27, 2023.
| 1 |
MDWD
|
Severe burns - pediatric
|
Phase 3
|
2021-07-20 00:00:00
|
Phase 3 top-line data met primary endpoints - July 20, 2021.
| 0 |
CYCN
|
Heart failure HFpEF
|
Phase 2
|
2019-10-30 00:00:00
|
Phase 2 trial did not meet primary endpoint - October 30, 2019.
| 1 |
KRTX
|
Schizophrenia
|
Phase 3
|
2023-03-20 00:00:00
|
Phase 3 trial met primary endpoint, noted March 20, 2023.
| 0 |
CLVS
|
Ovarian Cancer - First-line maintenance treatment
|
PDUFA
|
2023-06-26 00:00:00
|
Company went bankrupt in 2022 not information disclosed about the PDUFA.
| 0 |
RYTM
|
POMC deficiency obesity / Leptin Receptor Deficiency Obesity
|
Approved
|
2020-11-27 00:00:00
|
FDA approval announced November 27, 2020.
| 1 |
LLY
|
Inherited Alzheimer's disease
|
Phase 2/3
|
2020-02-10 00:00:00
|
Phase 3 trial did not meet primary endpoint.
| 1 |
LLY
|
Nonsquamous NSCLC
|
CRL
|
2022-03-24 00:00:00
|
CRL announced March 24, 2022.
| 0 |
IONS
|
Alzheimer's disease
|
Phase 1/2
|
2023-03-29 00:00:00
|
Phase 1b trial of 1b/2 study met its primary objective of safety and tolerability. Phase 1b LTE study results showed that dosing reduced biomarkers of soluble tau in CSF (t-tau and p-tau181) in a dose-dependent and sustained manner, with all dose groups showing approximately a 60% reduction from baseline CSF tau levels by the end of the LTE .Phase 2 trial in progress, noted March 29, 2023.
| 1 |
NBIX
|
Congenital Adrenal Hyperplasia (CAH) - children
|
Phase 3
|
2023-10-05 00:00:00
|
Phase 3 trial met primary endpoint, noted October 5, 2023.
| 0 |
MNKD
|
Type 1/2 diabetes
|
Approved
|
2014-06-27 00:00:00
|
Approved June 27, 2014.
| 1 |
CRBP
|
Dermatomyositis
|
Phase 3
|
2021-06-24 00:00:00
|
Phase 3 trial did not meet primary endpoint - June 24, 2021.
| 1 |
MIRM
|
Alagille Syndrome (ALGS)
|
Approved
|
2021-09-29 00:00:00
|
Approved September 29, 2021.
| 1 |
ARAV
|
Pancreatic Adenocarcinoma
|
Phase 1b
|
2023-05-25 00:00:00
|
Phase 1b data from ASCO reported that the median overall survival (OS) for patients with trough levels above the minimal batiraxcept efficacious concentration is greater than 15 months, and one patient demonstrated a complete response from 10 months to 20 months and is still on study, noted May 25, 2023.
| 1 |
SRRK
|
Solid Tumors
|
Phase 1
|
2023-11-03 00:00:00
|
Phase 1 biomarker data presented at SITC showed promising anti-tumor activity in heavily pretreated clear cell renal cell carcinoma (ccRCC) patients. Objective response rate (ORR) of 21.4% and disease control rate of 57%, noted November 3, 2023.
| 1 |
MRK
|
Clostridium difficile infections (CDI)
|
Approved
|
2020-01-27 00:00:00
|
FDA Approval announced January 27, 2020.
| 1 |
CARA
|
Stage 3-4 Chronic Kidney Disease-Associated Pruritus
|
Phase 2
|
2019-12-03 00:00:00
|
Phase 2 data met primary endpoint but secondary missed - December 3, 2019.
| 0 |
IMCR
|
Cutaneous melanoma (mCM)
|
Phase 1b
|
2022-06-05 00:00:00
|
Phase 1b data to be presented at ASCO showed 1 year overall survival (OS) of approximately 75% in heavily pre-treated mCM compared to benchmark of 55%.
| 1 |
BMY
|
Spinal Muscular Atrophy (SMA)
|
Phase 3
|
2023-09-14 00:00:00
|
Phase 3 trial to continue dosing, noted November 9, 2022. Phase 3 dosing completed, noted September 14, 2023.
| 0 |
ALLO
|
Large B-cell lymphoma
|
Phase 1
|
2023-06-15 00:00:00
|
Additional data reported at ICML across all 33 patients the CR rate was 42% with 30% maintaining a CR at Month 6. Results indicated complete responses are more common with lymphodepletion regimens containing 90 mg of ALLO-647 (FCA90). Median duration of response for both the overall population and the patients treated with the Phase 2 regimen (n=12) was 23.1 months, noted June 15, 2023.
| 1 |
EWTX
|
Duchenne Muscular Dystrophy (DMD)
|
Phase 2
|
2023-10-26 00:00:00
|
Phase 2 cohort in boys initiated, October 26, 2023.
| 0 |
PFE
|
Persistent Pulmonary Hypertension (PPHN)
|
Phase 3
|
2019-06-28 00:00:00
|
Phase 3 trial did not meet primary endpoint - June 28, 2019.
| 1 |
CNTX
|
Ovarian cancer
|
Phase 2
|
2022-06-06 00:00:00
|
Phase 2 data presented at ASCO reported that a 12-month PFS rate of 20.1% and a CBR of 35.7% in patients with GCT. No objective responses were observed, noted June 6, 2022.
| 1 |
OVID
|
Adolescents with Angelman syndrome
|
Phase 3
|
2020-12-01 00:00:00
|
Phase 3 trial did not meet primary endpoint - December 1, 2020.
| 1 |
AKRO
|
Nonalcoholic steatohepatitis (NASH)
|
Phase 2b
|
2023-10-10 00:00:00
|
Phase 2b top line data showed that a trend was observed for the primary endpoint of fibrosis improvement at 36 weeks, with 22% and 24% of the 28mg and 50mg EFX-treated groups, respectively, compared with 14% for placebo, noted October 10, 2023.
| 1 |
CRVS
|
Peripheral T-cell lymphoma (PTCL)
|
Phase 1b
|
2023-06-15 00:00:00
|
Phase 1/1b antitumor response data presented at the ICML demonstrated the potential of ITK inhibition to provide a novel immunotherapy mechanism of action for cancer therapy, noted June 15, 2023. Company plans to meet with FDA during 3Q 2023 to discuss Phase 3 design.
| 1 |
OCGN
|
COVID-19 vaccine
|
Phase 3
|
2021-07-02 00:00:00
|
Phase 3 data from partner Bharat Biotech noted efficacy rate of 78%; 93% against severe disease; 65% against Delta variant
| 0 |
SNY
|
High low-density lipoprotein (LDL) cholesterol
|
Approved
|
2017-04-25 00:00:00
|
sBLA Approval announced April 25, 2017.
| 1 |
TAK
|
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
|
Phase 3
|
2023-06-10 00:00:00
|
Phase 3 data presented at EHA showed that Ponatinib was superior to imatinib in combination with reduced-intensity chemotherapy in the front-line setting for patients with Ph+ ALL, with a significantly higher MRD-neg CR rate at EOI. Ponatinib was associated with deeper and more durable responses, with a trend toward improved EFS and comparable safety vs imatinib, noted June 9, 2023.
| 1 |
IMRA
|
b-thalassemia
|
Phase 2b
|
2021-11-16 00:00:00
|
Phase 2b interim data showed an uptrend observed in transfusion-dependent subjects treated with higher dose for reduced transfusion burden. The dose was generally well-tolerated in this patient population.
| 1 |
VIR
|
COVID-19 antibody
|
Approved
|
2021-05-26 00:00:00
|
FDA Emergency Use Authorization filing approval announced May 26, 2021.
| 1 |
AMGN
|
Migraine
|
Approved
|
2018-05-17 00:00:00
|
Approval announced May 17, 2018.
| 1 |
GMAB
|
Cervical Cancer
|
Approved
|
2021-09-20 00:00:00
|
Approved September 20, 2021.
| 1 |
FGEN
|
Pancreatic cancer
|
Phase 2
|
2017-01-17 00:00:00
|
Phase 2 abstract released January 17, 2017.
| 0 |
BGNE
|
Relapsed or refractory mantle cell lymphoma (MCL)
|
Approved
|
2019-11-14 00:00:00
|
FDA Approval announced November 14, 2019.
| 1 |
MIRM
|
Cerebrotendinous xanthomatosis (CTX)
|
Phase 3
|
2023-10-02 00:00:00
|
Phase 3 data met the primary endpoint of reduction in bile alcohols (urine 23S-pentol) was highly statistically significant, noted October 2, 2023.
| 1 |
TBPH
|
Asthma
|
Approved
|
2020-09-09 00:00:00
|
FDA approval announced September 9, 2020.
| 1 |
AGEN
|
Soft Tissue Sarcoma
|
Phase 2
|
2021-09-17 00:00:00
|
Phase 2 data showed in 125 patients, the objective response rate (ORR) was 26%, with 9% of patients achieving a complete response (CR), and 17% of patients achieving a partial response (PR), noted September 17, 2021.
| 1 |
NVAX
|
COVID-19 vaccine (booster)
|
Phase 3
|
2022-11-08 00:00:00
|
Phase 3 data reported that BA.1 vaccine candidate met its primary strain-change endpoint, noted November 8, 2022.
| 0 |
AMLX
|
Alzheimer's Disease
|
Phase 2
|
2022-04-02 00:00:00
|
Phase 2 results reported that treatment was well-tolerated, with a majority of treatment-emergent adverse events (TEAEs) being gastrointestinal, noted April 2, 2022.
| 1 |
CNSP
|
Glioblastoma (GBM) (adult)
|
Phase 2
|
2023-08-14 00:00:00
|
Phase 2 interim update demonstrated its capability to be an innovative treatment in GBM that is safe and well tolerated, which has the potential to be a novel and effective therapy for this disease, noted August 14, 2023.
| 1 |
AZN
|
Refractory generalized myasthenia gravis (gMG)
|
Approved
|
2017-10-23 00:00:00
|
Approval announced October 23, 2017.
| 1 |
GSK
|
HIV-1
|
Phase 3
|
2023-02-23 00:00:00
|
Phase 3b data reported that the trial achieved primary endpoint, noted February 23, 2023.
| 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.